Primetime for antiangiogenic therapy

Current Opinion in Neurology

Volumn 22, Issue 6, 2009, Pages 639-644

  Tabatabai, Ghazaleh ^a   Stupp, Roger ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiogenesis; Antiangiogenic therapy; Malignant glioma

Indexed keywords

ALPHAVBETA5 INTEGRIN; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CEDIRANIB; CILENGITIDE; COLLAGEN TYPE 4; ENZASTAURIN; GELATINASE A; GELATINASE B; IRINOTECAN; PLATELET DERIVED GROWTH FACTOR C; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TEMOZOLOMIDE; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB; VITRONECTIN RECEPTOR; XL 184;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BLEEDING; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; CANCER RESISTANCE; CANCER SURVIVAL; DRUG TARGETING; GLIOBLASTOMA; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; RECURRENT CANCER; REVIEW; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; GLIOMA; HUMANS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 74049110376     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328332ba28     Document Type: Review

References (56)

1. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7:987-989.
2. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxyge nation, angiopoietin-1 and matrix metalloproteinases. Cancer Cell 2004; 6:553-563.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide in glioblastoma. N Engl J Med 2005; 10:997-1003.
4. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblas-tomas in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459-466.
5. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006; 1:97-117.
6. Hanahan D, Folkman J. Parameters and emerging mechanisms of the angio-genic switch during tumorigenesis. Cell 1996; 86:353-364.
7. Hanahan D, Weinberg R. The hallmarks of cancer. Cell 2000; 100:57-70.
8. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727-739.
9. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114:97-109.
10. Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther Targets 2009; 9:231-240.
11. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
12. Stefanik DF, Rizkalla LR, Soi A, et al. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res 1991; 51:5760-5765.
13. Laterra J, Nam M, Rosen E, et al. Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo. Lab Invest 1997; 76:565-577.
14. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 2005; 7:436-451.
15. Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006; 9:287-300.
16. Wild-Bode C, Weller M, Wick W. Molecular determinants of glioma cell migration and invasion. J Neurosurg 2001; 94:978-984.
17. Maurer GD, Tritschler I, Adams B, et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolo-mide in vitro. Neuro Oncol 2009; Feb [Epub ahead of print].
18. Dirks PB. Brain tumor stem cells: bringing order to the chaos of brain cancer. J Clin Oncol 2008; 26:2916-2924.
19. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor cells. Cancer Cell 2007; 11:69-82.
20. Hambardzumyan D, Becher OJ, Rosenblum MK, etal. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 2008; 22:436-448.
21. Hambardzumyan D, Becher OJ, Holland EC. Cancer stem cells and survival pathways. Cell Cycle 2008; 7:1371-1378.
22. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66:7843-7848.
23. Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007; 7:733-736.
24. Folkins C, Man S, Xu P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the stem-like cell faction in glioma xenograft tumors. Cancer Res 2007; 67:3560-3564.
25. Hurtwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucoverin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
26. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract #342]. In: World Federation of Neuro-Oncology Second Quadrennial Meeting; 5-8 May 2005; Edinburgh, Scotland.
27. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25:4722-4729. (Pubitemid 350086473)
28. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740-745.
29. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95.
30. Wick W, Puduvalli VK, Chamberlain M, et al. Enzastaurin versus lomustine in the treatment of recurrent intracranial glioblastomas: a phase III study. J Clin Oncol (in press).
31. Reardon D, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastomas multiforme. J Clin Oncol 2008; 26:5610-5617.
32. Gonzales J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol 2009; 67:323-326.
33. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009; 75:156-163.
34. Wachsberger PR, Burd R, Cardi C, et al. VEGF trap in combination with radiotherapy improves tumor control in U87 glioblastoma. Int J Radiat Oncol Biol Phys 2007; 67:1526-1537.
35. Gomez-Manzano C, Holash J, Fueyo J, et al. VEGF trap induces antiglioma effect at different stages of disease. Neuro Oncol 2008; 10:940-945.
36. Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009; 27:2542-2552.
37. Teicher B, Alvarez E, Menon K, et al. Antiangiogenic effects of a protein kinase C beta-selective small molecule. Cancer Chemother Pharmacol 2002; 49:69-77.
38. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C beta-selective inhibitor, enzastaurin (LY317615.HCl) suppresses signaling through the AKT pathway, induces apoptosis, suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65:7462-7469.
39. Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol 2007; 61:153-161.
40. Rieger J, Lemke D, Maurer G, et al. Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. J Neurochem 2008; 106:2436-2448.
41. Taga T, Suzuki A, Gonzales-Gomez I, et al. Alpha v-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002; 98:690-697.
42. Mikkelsen T, Brodie C, Finiss S, et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 2009; 124:2719-2727.
43. Eskens FA, Dumez H, Hoekstra R, et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003; 39:917-926.
44. MacDonald TJ, Stewart CF, Kocak M, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 2008; 26:919-924.
45. Stupp R, Goldbrunner R, Neyns B, et al. Phase I/IIa trial of cilengitide (EMD 121974) and temozolomide with concomitant radiotherapy, followed by temolzolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma [abstract]. J Clin Oncol 2007; 25:2000.
46. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009; 15:392-400.
47. Weller M, Reardon D, Nabors B, Stupp R. Will integrin inhibitors have proangiogenic effects in the clinic? Nat Med 2009; 15:726.
48. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997; 390:335-336.
49. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas. Efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70:779-787.
50. Kunkel P, Ulbricht U, Bohle P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61:6624-6628.
51. Paez-Ribes M, Allen E, Hucock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-231.
52. Carmeliet P, De Smet F, Loges S, Mazzone M. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 2009; 6:315-326.
53. DiTomaso E, London N, Fuja D, et al. PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS One 2009; 4:e5123.
54. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131:463-475.
55. Fischer C, Mazzone M, Jockx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for antiangiogenic therapy? Nat Rev Cancer 2008; 8:942-956.
56. Gerstner ER, Sorensen AG, Jain RK, Batchelor TT. Advances inneuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol 2008; 21:728-735.